CSX, TG Therapeutics, Bill Barrett Upgraded

Analysts are weighing in on transportation concern CSX Corporation (NASDAQ:CSX), drugmaker TG Therapeutics Inc (NASDAQ:TGTX), and oil-and-gas stock Bill Barrett Corporation (NYSE:BBG). Here's a roundup of today's bullish brokerage notes on CSX, TGTX, and BBG shares.

Analysts Cheer CSX CEO Announcement

Analysts are raising their outlooks on CSX this morning, after the company named Hunter Harrison as CEO. The stock has received price target hikes to $60, $58, and $47 from Deutsche Bank, Citigroup, and Stifel, respectively. The shares have already hit a record high of $50.15 out of the gate, and was last seen at $49.84 -- roughly doubling in value year-over-year. Meanwhile, put buying has been popular at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). CSX Corporation has a 10-day put/call volume ratio 1.10 across these exchanges, which ranks in the bearishly skewed 73rd percentile of its annual range. 

Wall Street Stays Bullish On TG Therapeutics

After soaring on Monday thanks to upbeat trial results from its leukemia drug, TGTX is up 1% today at $10.30. Analysts are eyeing extended upside, too, with SunTrust Robinson increasing its price target to $26 from $19, and Ladenburg Thalmann raising its price target to $30 from $28. This bullish attention is nothing new for the stock, however, as all six brokerage firms covering TG Therapeutics Inc say it's a "strong buy." 

Brokerages Split On Bill Barrett 

BBG is up 3.1% at $5.06, after Canaccord Genuity upgraded the stock to "buy" from "hold" -- though it also trimmed its price target to $7 from $8. Deutsche Bank also cut its price target, dropping it to $8 from $9. Pessimism does seem warranted, with Bill Barrett Corporation well below its 12-month high of $9.38 from last April. No matter your view, it's an attractive time to buy BBG options. This is based on a Schaeffer's Volatility Index (SVI) of 61%, which ranks in the low 15th annual percentile, pointing toward low volatility expectations being priced into near-term contracts.